Related Experiment Videos
Comparative immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines
1Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St Louis, MO 63110.
Insights
Differences in Haemophilus b conjugate vaccine immunogenicity are minimal in older children but significant in 2-month-old infants. All vaccines prime infants for future immune responses, potentially offering protection against disease.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Haemophilus b infections pose a significant risk to infants.
- Polysaccharide-protein conjugate vaccines are crucial for preventing Haemophilus b disease.
- Understanding vaccine immunogenicity in different age groups is vital for optimizing vaccination strategies.
Purpose of the Study:
- To compare the immunogenicity of three licensed Haemophilus b polysaccharide-protein conjugate vaccines.
- To assess vaccine responses in both infants (2 months) and older children (17–19 months).
- To evaluate the priming effect of these vaccines on subsequent immune responses.
Main Methods:
- Clinical study involving infants and children receiving one of three Haemophilus b conjugate vaccines.
- Measurement of antibody responses following primary vaccination and booster doses.
- Comparison of immunogenicity based on age at vaccination and vaccine type.
Main Results:
- Minor immunogenicity differences were observed in children aged 17–19 months.
- Significant differences in immunogenicity were found in 2-month-old infants.
- PRP-OMPC elicited a strong primary response in infants, while HbOC and PRP-D required multiple doses.
- All vaccines demonstrated a priming effect, enhancing antibody response to booster doses.
Conclusions:
- Age significantly impacts the immunogenicity of Haemophilus b conjugate vaccines.
- PRP-OMPC shows superior primary immunogenicity in young infants compared to HbOC and PRP-D.
- Vaccine-induced immune priming may contribute to protection against Haemophilus b disease, even without high initial antibody levels.
Abstract:
There are only minor differences in the immunogenicity of the three Haemophilus b polysaccharide-protein conjugate vaccines licensed in the US when tested in children 17 to 19 months of age. In contrast, there are much greater differences in immunogenicity in 2-month-old infants. At this age, a single dose of PRP-OMPC evokes a strong primary antibody response, whereas repeated doses of HbOC or PRP-D are required to evoke an antibody response. These differences in immunogenicity are noteworthy, but they are not necessarily correlated with differences in the ability of different conjugate vaccines to confer protection against disease. Vaccination with all three of the conjugate vaccines primes infants for the ability to make a booster antibody response to reimmunization with unconjugated PRP vaccine and, possibly, to exposure to the encapsulated bacteria. Although unproven, this priming may be sufficient to confer protection against disease even in the absence of a 'protective' level of serum antibody.